not much the company can do. I think they are doing everything they said they would do in terms of the product. its just the market for biotech and anything with a long gestation period such as this is being thrown in the bin.......maybe in time something will come out of it but its surely off to a very bad start at the very least!
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-6
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EBR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
-0.020(1.90%) |
Mkt cap ! $317.3M | |||
| Open | High | Low | Value | Volume |
| $1.04 | $1.06 | $1.01 | $117.0K | 113.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 13004 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 9900 | 1 |
View Market Depth
| Last trade - 16.10pm 19/06/2024 (20 minute delay) ? |
| EBR (ASX) Chart |